Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1576 studies found for:    Open Studies | "Lymphatic Diseases"
Show Display Options
Rank Status Study
1 Recruiting National Lymphatic Disease and Lymphedema Registry
Condition: Lymphedema
Intervention:
2 Recruiting Study of Autoimmune Lymphoproliferative Syndrome (ALPS)
Conditions: Autoimmune Disease;   Lymphatic Disease;   Lymphoproliferative Disorder;   Canale-Smith Syndrome
Intervention:
3 Recruiting Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Conditions: Lymphatic Diseases;   Hematopoietic Malignancy
Intervention: Biological: Umbilical Cord Blood (UCB)
4 Recruiting Sildenafil for the Treatment of Lymphatic Malformations
Conditions: Lymphatic Malformations;   Lymphatic Diseases
Interventions: Drug: Sildenafil 20 mg tablets;   Other: Placebo tablets (resembling Revatio)
5 Recruiting Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders
Conditions: Lymphangiomatosis;   Lymphedema;   Lymphangiectasia;   Pulmonary Lymphangiectasia
Intervention:
6 Unknown  Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders
Condition: Lymphedema
Intervention: Drug: near-infrared fluorescence imaging
7 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Non-hodgkin Lymphoma or Multiple Myeloma
Conditions: Non-Hodgkin Lymphoma;   Multiple Myeloma
Intervention: Drug: ABT-199
8 Available Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
Conditions: Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Lymphomas;   Bone Marrow Failure;   Hemoglobinopathy;   Immune Deficiency;   Osteopetrosis;   Cytopenias;   White Blood Cell Abnormalities;   Red Blood Cell Abnormalities
Intervention: Biological: CD34+ enriched, T Cell Depleted donor stem cell product
9 Recruiting A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
10 Recruiting E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
11 Recruiting Zevalin-Beam for Aggressive Lymphoma
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation
12 Unknown  TREatment of degeNerative and Neoplastic Diseases With Rituximab
Condition: Diffuse Large B Cell Lymphoma
Intervention: Biological: Rituximab
13 Unknown  Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy
Conditions: Lymphoma;   Kikuchi's Disease
Intervention:
14 Recruiting Bronchoscopic Sampling Techniques in Sarcoidosis
Conditions: Mediastinal Lymph Node Enlargement;   Sarcoidosis;   Tuberculosis;   Lymphomas
Interventions: Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB);   Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA);   Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes;   Procedure: Bronchoalveolar lavage (BAL);   Procedure: Endobronchial forceps biopsy
15 Recruiting Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL
Conditions: Anaplastic Large Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Drug: belinostat;   Biological: rituximab;   Radiation: yttrium Y 90 ibritumomab tiuxetan
16 Recruiting Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: irradiation therapy;   Biological: G-CSF;   Drug: Cytarabine
17 Not yet recruiting Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Conditions: Leukemia;   Lymphoma
Intervention: Biological: Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
18 Unknown  Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Rituximab
19 Recruiting Study of the Disease Process of Lymphangioleiomyomatosis
Conditions: Lung Disease;   Pneumothorax;   Tuberous Sclerosis
Intervention:
20 Recruiting GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma
Condition: Follicular Lymphoma
Interventions: Biological: GP2013;   Biological: rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years